Lopid Indocin Naprosyn Morphine |
Lamotrigine ADVERSE REACTIONS Clinical Trial Adverse Drug Reactions Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates. Hypertension. Lamotrigine medication rash100000 Lamotdigine AUC, ng.h mL.
Visit webmd for additional health information on multiple sclerosis.
Conversion to monotherapy with LAMICTAL with AEDs other than carbamazepine, phenobarbital, phenytoin, primidone, or valproate. Usual Maintenance Dose for Epilepsy: The usual maintenance doses identified in Tables 9-12 are derived from dosing regimens employed in the placebo-controlled adjunctive studies in which the efficacy of LAMICTAL was established. In patients receiving multidrug regimens employing carbamazepine, phenytoin, phenobarbital, or primidone without valproate, maintenance doses of adjunctive LAMICTAL as high as 700 mg day have been used. In patients receiving valproate alone, maintenance doses of adjunctive LAMICTAL as high as 200 mg day have been used. The advantage of using doses above those recommended in Tables 9-13 has not been established in controlled trials. Discontinuation Strategy for Patients With Epilepsy: For patients receiving LAMICTAL in combination with other AEDs, a reevaluation of all AEDs in the regimen should be considered if a change in seizure control or an appearance or worsening of adverse experiences is observed. If a decision is made to discontinue therapy with LAMICTAL, a step-wise reduction of dose over at least 2 weeks approximately 50% per week ; is recommended unless safety concerns require a more rapid withdrawal see PRECAUTIONS ; . Discontinuing carbamazepine, phenytoin, phenobarbital, or primidone should prolong the half-life of lamotrigine; discontinuing valproate should shorten the half-life of lamotrigine. Target Plasma Levels for Patients With Epilepsy: A therapeutic plasma concentration range has not been established for lamotrigine. Dosing of LAMICTAL should be based on therapeutic response. Bipolar Disorder: The goal of maintenance treatment with LAMICTAL is to delay the time to occurrence of mood episodes depression, mania, hypomania, mixed episodes ; in patients treated for acute mood episodes with standard therapy. The target dose of LAMICTAL is 200 mg day 100 mg day in patients taking valproate, which decreases the apparent clearance of lamotrigine, and 400 mg day in patients not taking valproate and taking either carbamazepine, phenytoin, phenobarbital, primidone, or rifampin, which increase the apparent clearance of lamotrigine ; . In the clinical trials, doses up to 400 mg day as monotherapy were evaluated, however, no additional benefit was seen at 400 mg day compared to 200 mg day see CLINICAL STUDIES: Bipolar Disorder ; . Accordingly, doses above 200 mg day are not recommended. Treatment with LAMICTAL is introduced, based on concurrent medications, according to the regimen outlined in Table 14. If other psychotropic medications are withdrawn following stabilization, the dose of LAMICTAL should be adjusted. For patients discontinuing valproate, the dose of LAMICTAL should be doubled over a 2-week period in equal weekly increments see Table 15 ; . For patients discontinuing carbamazepine, phenytoin, phenobarbital, primidone, or rifampin, the dose of LAMICTAL should remain constant for the first week and then should be decreased by half over a 2-week period in equal weekly decrements see Table 15 ; . The dose of LAMICTAL may then be further adjusted to the target dose 200 mg ; as clinically indicated and loxitane. In his editorial Competency for new prescribers, Professor Anthony Smith, Newcastle Mater Hospital and University of Newcastle, discusses extending prescribing rights to non-medical health professionals. He discusses prescribing competency, and the need for adequate training and ongoing evaluation of non-medical health professionals prescribing within limited formularies to an appropriately high standard. "The issue of prescribing extension brings into focus the competence of doctors and pharmacists the current prescribers in our society, " says Professor Smith. "Prescribing worldwide is not uniformly of high quality for example, over-prescription of antibiotics ; and until recently training in prescribing has been inadequate." For patients with bipolar disorders, authors Dr David Pyle Prince of Wales Hospital ; and Professor Philip Mitchell University of NSW ; discuss various maintenance therapies. "Bipolar disorders are highly recurrent for most patients, and it is the recurring nature of the condition that, unless adequately treated, gradually takes its toll in terms of the patient's capacity to maintain relationships, career and self-esteem." Lithium is still regarded as the `gold standard' therapy but many patients are unable to tolerate it, and it has limited effectiveness for the depressive phase of bipolar disorders. The authors also examine anticonvulsants including lamotrigine, antipsychotics such as olanzapine, and combination therapy. The authors conclude that "while none of the newer drugs has been shown to be more effective than lithium, they are better tolerated by some patients". For the complete articles visit the Australian Prescriber website australianprescriber ENDS and loxapine. Lamotrigine chew tabsVertebrates is high . The virus can also be transmitted in urban and other ecologic settings, although the intensity of transmission is ogten much less than in endemic, rice-producing areas. JE cases have been reported among urban residents and travellers to Asian cities who had little or no rural exposure and were likely infected by urgan Culex species 2 ; . In addition, because wading birds e.g., egrets ; and large mammals other than swine can serve as amplifying hosts, JE virus transmission can occur in areas where swine are not raised. JE virus-infected persons do not have high- titer viremia and are therefore considered "dead-end" hosts. A single, formalin-inactivated, mouse brain-derived, JE vaccine is licensed for use in the United States in persons aged 1 year. The preferred primary vaccination series consists of three doses administered at 0, 7, and 30 days, but an accelerated schedule consisting of three doses administered at 0, 7, and 14 days can be used when the longer schedule is impractical or inconvenient because of time constraints. With either schedule, the primary series should be completed at least 10 days before travel to allow an adequate immune response and monitoring of adverse events AE ; after vaccination; therefore, JE vaccination should begin at least 24 days before travel abroad. In addition to a moderate rate of local side effects 2 ; , rare and more serious neurologic e.g., encephalitis ; and allergic AE e.g., urticaria or angioedema ; have been reported 9 ; . JE vaccine is not recommended for all travellers to Asia. For each traveller, careful consideration of the potential risks and benefits of vaccination should be made by a health-care provider familiar with the person's itinerary, the vaccine, and the current CDC recommendations for its use 2 ; . In general, vaccine should be offered to persons spending 1 month in JE-endemic areas during the transmission season, especially if travel will include rural areas. Under specific circumstances, vaccine should be considered for persons spending 1 month in JE-endemic areas e.g., travellers to areas experiencing epidemic transmission and persons whose activities, such as extensive outdoor activities in rural areas, place them at high risk for exposure ; . In all instances, travellers should be advised to take personal precautions to reduce exposure to mosquito bites e.g., avoidance of mosquitoes and use of repellents and protective clothing. Advantages Assess "net" effect of mutations on drug susceptibility. Provide data on cross-resistance and lercanidipine and lamotrigine, because lamotrigine effects. K-PhOS Mf K-PhOS NO. 2 KALeTRA KePPRA . ketoconazole . ketoconazole crm, shampoo, 2% ketoprofen, Nf eR labetalol lactulose . 25, 26 LAMIcTAL chew tabs, 2mg; tabs . LAMISIL tabs . lamotrigine chew tabs . LANceT deVIceS, LANceTS; AccU-cheK SOfTcLIX, ASceNSIA MIcROLeT, bd . 37, 38 LANTUS . leflunomide . LeUcOVORIN cALcIUM . 17 leucovorin calcium . LeUKeRAN . leuprolide . LeVAQUIN . levobunolol eye soln . levonorgestrel ethinyl estradiol, 0.1 20 Aviane, Lessina, Lutera, Sronyx . levonorgestrel ethinyl estradiol, 0.15 30 Levora, Portia . levonorgestrel ethinyl estradiol, triphasic enpresse, Trivora 18 levothyroxine includes Levoxyl; Nf Levothroid . LeXAPRO . LeXIVA . LIALdA . lidocaine prilocaine . lidocaine crm, 3%; jelly, 2%; lotn, 3%; oint, 5%; soln, 4% lidocaine viscous . LIdOdeRM LINdANe LIPITOR . LIPRAM PN UL . lisinopril . lisinopril hydrochlorothiazide . LIThIUM cARbONATe caps, 600mg; tabs, 300mg . lithium carbonate IR, eR . lithium citrate syrup . lorazepam . LORAZePAM INTeNSOL . LOTeMAX . LOTReL . lovastatin LOVeNOX . loxapine . LUPRON dePOT . LYSOdReN . MAcROdANTIN 25mg MALARONe . MATULANe mebendazole . medroxyprogesterone acetate . medroxyprogesterone inj, 150mg mL. Lamotrigine effexorGENERIC: LAMOTRIGINE BRAND: LAMICTAL INDICATION: 1 ; Partial seizures or generalized seizures with LGS. Criteria: a ; Failure contraindication of two formulary anticonvulsants. b ; Patient has been maintained on requested anticonvulsant. GENERIC: LATANOPROST BRAND: XALATAN INDICATIONS: 1 ; For reduction of elevated IOP 2 ; Open angle glaucoma and ocular hypertension Criteria: a ; Failure of treatment trials with two formulary agents. GENERIC: LEUPROLIDE BRAND: LUPRON INDICATIONS: 1 ; Advanced prostate cancer 2 ; Central precocious puberty 3 ; Endometriosis 4 ; Uterine leiomyomata fibroids ; Criteria: a ; Diagnosis of advanced prostate cancer, precocious puberty or fibroids; or b ; For the diagnosis of endometriosis, failure of NSAIDS and oral contraceptives or endometriosis diagnosed by laparoscopy. * Note: This agent is ordinarily administered at the physician's office. For injectable medications administered by a healthcare professional, please refer to the "Policy for Injectable Drugs" in the beginning of this formulary. The study, conducted at 19 sites in five European countries, found that a daily dose of the drug fully eliminated seizures in 24 percent of patients with at least four partial-onset seizures per month who did not respond to other treatments. There were no gender- or age-related differences noted in. Lamotrigine Broad spectrum and first line [ less teratogenic than VPA] Dosing slow to minimise side effects usually 25mg a day increasing every 2 weeks, b.d. dosing. Max dose around 400mg a day. Interactions VPA , CBZ and PHT Idiosyncratic reactions in up to. January 2000, Vol. 6#1 Do Not Use! Oseltamivir TAMIFLU ; : Another Expensive New Flu Drug Do Not Use Until November 2004: Rabeprazole ACIPHEX ; -- The Third Proton-Pump Inhibitor Update on Sildenafil VIAGRA ; For Sexual Dysfunction New Research on Direct-to-Consumer Prescription Drug Advertising Ineffective and Dangerous Dietary Supplements: S-adenosyl-methionine SAMe ; For Depression and the Diet Pill Tiratricol TRIAX ; Update on European Regulators and Diet Drugs: Sibutramine MERIDIA ; Hits a Snag February 2000, Vol. 6#2 Do Not Use: Moxifloxacin AVELOX ; -- The Ninth Fluoroquinolone Antibiotic Hypericum Extract from ST. JOHN'S WORT ; in the Treatment of Moderate Depression Further Evaluation of the Flu Drug Zanamivir RELENZA ; March 2000, Vol. 6#3 Health Hazard! "Wilson's Syndrome"-- Quackery and Pharmaceutical Trickery Pharmacy Compounding ; 70 Deaths Now Linked to the Dangerous Heartburn Drug Cisapride PROPULSID ; The United Kingdom Prospective Diabetes Study UKPDS ; --Reducing Long-Term Complications of Type-2 Diabetes April 2000, Vol. 6#4 Liver Toxicity Reported With the New Diabetes Drug Rosiglitazone AVANDIA ; Save Your Money: Do Not Use Vitamin E for Preventing Heart Attack and Stroke New Drug Interaction Warnings for the Antifungal Drug Itraconazole SPORANOX ; California Health Director Warns Consumers About Prescription Drugs in Herbal Products Update on Adverse Effects: Bupropion ZYBAN ; for Smoking Cessation May 2000, Vol. 6#5 Six Drug Withdrawals in 30 Months on Safety Grounds Dangerous Heartburn Drug Cisapride PROPULSID ; Withdrawn But Remains Available The Long Overdue Withdrawal of the Diabetes Drug Troglitazone REZULIN ; New Recommendations on the Use of the Alpha-blockers Doxazosin CARDURA ; , Prazosin MINIPRESS ; , Terazosin HYTRIN ; in the Treatment of High Blood Pressure New Warnings! Clinically Important Drug Interactions with ST. JOHN'S WORT June 2000, Vol. 6#6 Dangerous Gap in the Drug Safety System--Companies May Be Failing to Keep Their Post-Marketing Research Promises Canadian Update on the Arthritis Drug Celecoxib CELEBREX ; Confirms HRG's Earlier `Five-year Rule' Warning About Its Use `Gold Standard' Study Shows No Detectable Benefit Derived from Coenzyme Q10 for Congestive Heart Failure Patients Buyer Beware!--Shoddy Manufacturing and Labeling Practices Found in Dietary Supplements Containing Ephedra Life Threatening Blood Disorder Associated with the Use of Clopidogrel PLAVIX ; The Health Research Group Launches `eLetter' Web Site on Prescription Drugs for the Seriously Mentally Ill July 2000, Vol. 6#7 Do Not Use!--Meloxicam MOBIC ; -- Ever More Nonsteroidal Antiinflammatory Drugs NSAIDS ; Case Report: Why We List the Muscle Relaxant Cyclobenzaprine FLEXERIL ; as a "Do Not Use" Drug Postmenopausal Hormone Replacement Linked to Increased Risk of Blood Clots More Reports of Serious Drug Interactions Between ST. JOHN'S WORT and the Anti-organ Rejection Drug Cyclosporine NEORAL, SANDIMMUNE ; Warning! Do Not Use! Chinese Herbal Supplements Containing Aristolochic Acid August 2000, Vol. 6#8 Erroneous and Misleading Reports in Media About Prescription Drugs Do Not Use!--Alosetron LOTRONEX ; for the Treatment of Irritable Bowel Syndrome In Women Drug-Induced Stuttering Important Changes in Safety Labeling of Acne Drug Isotretinoin ACCUTANE ; Prescription Drug Dispensing Errors Alert: Lamotrlgine LAMICTAL ; Tablets and Terbinafine LAMISIL ; Tablets September 2000, Vol. 6#9 Do Not Use! The Antipsychotic Drug Thioridazine MELLARIL ; Do Not Use! Stroke Risk Reported With the Nonprescription Diet Drug and Nasal Decongestant Phenylpropanolamine DEXATRIM ; New Warnings about Zanamivir RELENZA ; Important Drug Warning! Life-threatening Inflammation of the Pancreas with Divalproex DEPAKOTE ; and Valproic Acid DEPAKENE ; October 2000, Vol. 6#10 Long-acting Calcium Channel Blockers Inferior to Older Blood Pressure Lowering Drugs in Preventing Heart Attacks and Heart Failure Do Not Use! Combination of Betamethasone and Clotrimazole LOTRISONE CREAM ; Especially in Children Under 12 or For Diaper Rash Review of Calcium Supplements: Ads Exaggerate Differences Victimizing the Vulnerable--Health Food Store Recommendations for Breast Cancer Patients November 2000, Vol. 6#11 Oral Prescription Drugs with Black Box Warnings: A List of 90 Drugs Review of Adverse Drug Reaction Reports for the Selective Serotonin Reuptake Inhibitor SSRI ; Antidepressants in the United Kingdom Update from the United Kingdom on Adverse Drug Reactions Reported for the Arthritis Drug Rofecoxib VIOXX ; December 2000, Vol. 6#12 Public Citizen Petitions to Ban All Uses of Phenylpropanolamine PPA ; in Over-the- Counter OTC ; Drug Products How You Can Report Adverse Reactions to the Food and Drug Administration Additional Warnings Are Added to Labeling for the Arthritis Drug Etanercept ENBREL ; NIH Stops Trial of Calcium Channel Blocker Amlodipine NORVASC ; in Treatment of High Blood Pressure Patients with Kidney Disease Do Not Use! Increasing Reports of Ischemic Colitis with the Irritable Bowel Syndrome Drug Alosetron LOTRONEX ; Penciclovir DENAVIR ; Cream: Expensive Treatment for Cold Sores See separate enclosure for cumulative index and order form.
|